LU92137I2
Untitled record
Abstract
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines (I) and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Term
6.3 yearsto projected expiry
Projected expiry 18 January 2033, counted from filing; an application has no term until it is granted.
- Priority
- Filed
- Published
- Today
- Projected expiry
231 members in 37 offices
Priority claims6
| Document | Office | Kind | Date |
|---|---|---|---|
| 74990505 | United States of America | P | |
| 81023106 | United States of America | P | |
| 85062506 | United States of America | P | |
| 85687206 | United States of America | P | |
| 85940406 | United States of America | P | |
| 2006047369 | United States of America | W |
Members231
| Document | Office | Kind | |
|---|---|---|---|
| US2007135461A1 | United States of America | A1 | |
| AU2006326548A1 | Australia | A1 | |
| CA2632466A1 | Canada | A1 | |
| WO2007070514A1 | World Intellectual Property Organization (WIPO) | A1 | |
| TW200728275A | Taiwan Province of China | A | |
| AR057995A1 | Argentina | A1 | |
| CR10065A | Costa Rica | A | |
| ECSP088540A | Ecuador | A | |
| KR20080079677A | Republic of Korea | A | |
| EP1966202A1 | European Patent Office (EPO) | A1 | |
| IL192019A0 | Israel | A0 | |
| IL192019D0 | Israel | D0 | |
| EA200870048A1 | Eurasian Patent Organization (EAPO) | A1 | |
| JP2009519340A | Japan | A | |
| CN101448826A | China | A | |
| US2009181959A1 | United States of America | A1 | |
| HK1124840A | Hong Kong, China | A | |
| HK1124840A1 | Hong Kong, China | A1 | |
| US7598257B2 | United States of America | B2 | |
| US2010022522A1 | United States of America | A1 | |
| NZ569015A | New Zealand | A | |
| EP2343298A1 | European Patent Office (EPO) | A1 | |
| EP2343299A1 | European Patent Office (EPO) | A1 | |
| EP2348023A1 | European Patent Office (EPO) | A1 | |
| US2011223210A1 | United States of America | A1 | |
| US2011224157A1 | United States of America | A1 | |
| EP1966202B1 | European Patent Office (EPO) | B1 | |
| AT525374T | Austria | T | |
| ATE525374T1 | Austria | T1 | |
| BRPI0619817A2 | Brazil | A2 | |
| JP2011252024A | Japan | A | |
| KR20110137406A | Republic of Korea | A | |
| PT1966202E | Portugal | E | |
| DK1966202T3 | Denmark | T3 | |
| HRP20110903T1 | Croatia | T1 | |
| SI1966202T1 | Slovenia | T1 | |
| ES2373688T3 | Spain | T3 | |
| PL1966202T3 | Poland | T3 | |
| EP2426129A1 | European Patent Office (EPO) | A1 | |
| AU2006326548B2 | Australia | B2 | |
| SG179430A1 | Singapore | A1 | |
| ECSP12008540A | Ecuador | A | |
| EP2455382A1 | European Patent Office (EPO) | A1 | |
| UA98449C2 | Ukraine | C2 | |
| ZA200805165B | South Africa | B | |
| RS52101B | Serbia | B | |
| EP2474545A1 | European Patent Office (EPO) | A1 | |
| HK1160111A1 | Hong Kong, China | A1 | |
| HK1160115A1 | Hong Kong, China | A1 | |
| HK1160137A1 | Hong Kong, China | A1 | |
| JP5017278B2 | Japan | B2 | |
| TW201240663A | Taiwan Province of China | A | |
| KR20120120462A | Republic of Korea | A | |
| KR20120120463A | Republic of Korea | A | |
| HK1168090A1 | Hong Kong, China | A1 | |
| KR101216055B1 | Republic of Korea | B1 | |
| FR13C0007I1 | France | I1 | |
| KR101218214B1 | Republic of Korea | B1 | |
| LTPA2013002I1 | Lithuania | I1 | |
| HK1171023A1 | Hong Kong, China | A1 | |
| US8415362B2 | United States of America | B2 | |
| US2013137681A1 | United States of America | A1 | |
| CN103214483A | China | A | |
| CN103214484A | China | A | |
| CN103254190A | China | A | |
| US8530485B2 | United States of America | B2 | |
| CA2632466C | Canada | C | |
| US8541425B2 | United States of America | B2 | |
| TWI410407B | Taiwan Province of China | B | |
| CR20130506A | Costa Rica | A | |
| KR101324737B1 | Republic of Korea | B1 | |
| ME01312B | Montenegro | B | |
| US2014005210A1 | United States of America | A1 | |
| US2014018374A1 | United States of America | A1 | |
| LU92137I2This record | Luxembourg | I2 | |
| FR13C0007I2 | France | I2 | |
| JP2014051531A | Japan | A | |
| EA019504B1 | Eurasian Patent Organization (EAPO) | B1 | |
| IL192019A | Israel | A | |
| KR101391900B1 | Republic of Korea | B1 | |
| IL231992A0 | Israel | A0 | |
| IL231992D0 | Israel | D0 | |
| US2014243360A1 | United States of America | A1 | |
| TW201434835A | Taiwan Province of China | A | |
| CN103214483B | China | B | |
| TWI468162B | Taiwan Province of China | B | |
| US8933086B2 | United States of America | B2 | |
| US8946245B2 | United States of America | B2 | |
| JP5710430B2 | Japan | B2 | |
| EP2343298B1 | European Patent Office (EPO) | B1 | |
| EP2348023B1 | European Patent Office (EPO) | B1 | |
| TW201522344A | Taiwan Province of China | A | |
| DK2348023T3 | Denmark | T3 | |
| US9079912B2 | United States of America | B2 | |
| ES2543903T3 | Spain | T3 | |
| ES2543904T3 | Spain | T3 | |
| US2015238492A1 | United States of America | A1 | |
| HRP20150837T1 | Croatia | T1 | |
| PT2348023E | Portugal | E | |
| CY1112762T1 | Cyprus | T1 |
Showing 100 of 231
Numbers
- Application
- 92137
Titles2
- English
- Ruxolitinib, or a pharmaceutically acceptable salt thereof
- French
- Ruxolitinib, ou un de ses sels pharmaceutiquement acceptables
Classification
- CPC, 20
- C07D471/04
- A61K31/519
- A61P17/00
- C07D487/04
- A61K31/395
- A61P35/00
- A61P37/00
- A61K31/573
- A61K45/06
- A61P31/12
- A61K9/0014
- A61K9/0053
- A61K9/20
- A61K31/437
- C07B59/002
- C07D417/04
- C07B2200/05
- A61P35/04
- A61P17/04
- A61P29/00